Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern India

Narayan Prasad¹,³, Akhilesh Jaiswal¹,³, Manas Ranjan Behera¹, Vikas Agarwal², Ravi Kushwaha¹, Dharmendra Bhadauria¹, Anupama Kaul¹ and Amit Gupta¹

¹Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; and ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Introduction: Tacrolimus (TAC) is the mainstay immunosuppressant for renal transplantation. A narrow therapeutic index, multiple drug interactions, and interindividual variability in pharmacokinetics make it obligatory to monitor therapeutic drug levels. The Multidrug resistance gene 1 (MDR1) and CYP3A5 gene polymorphism may blend to achieve the optimal level. The optimal dose as per body weight is difficult to single out in the early posttransplantation period. In this study, we aimed to analyze the melding effect of both gene polymorphisms and to elicit the dose depending on the combination of genetic single nucleotide polymorphisms (SNPs) in northern Indian transplant recipients, for whom data are limited.

Methods: The daily TAC dose, weight-adjusted doses (mg/kg per day), TAC trough blood concentration (average of at least 3 levels), dose normalized with a corresponding dose using TAC concentration/weight-adjusted dose ratio (ng/ml per mg/kg per day) of 248 patients were recorded. All recipients were genotyped for the SNPs of CYP3A5 at intron 3 A6986G (the *3 or *1 allele), MDR1 at exons 12 (C1236T), 21 (G2677A/T), and 26 (C3435T). We analyzed the blending effect of mutant SNPs of the MDR gene and CYP3A5 for optimized TAC levels.

Results: Among CYP3A5 genotypic variants, the dose-adjusted TAC level was significantly lower, and the TAC dose required to achieve the target level was significantly higher, in CYP3A5*1*1 (expressor) than that of CYP3A5*1*3 and CYP3A5*3*3. Of the MDR1 gene SNPs, only the G2677T/A homozygous mutant was significantly associated with TAC level, and it was strongly correlated with P-gp expression. The daily TAC dose requirement was highest with a combination of CYP3A5*1*1 and homozygous mutant TT + AA genotype of G2677T/A, and was lowest with CYP3A5*3*3 and wild-type GG of the G2677T/A genotype.

Conclusion: Both CYP gene and MDR1 gene polymorphism affect TAC dose requirements, and there is a need to look for both in an individual to achieve the target trough concentration.

Kidney Int Rep (2020) 5, 28–38; https://doi.org/10.1016/j.ekir.2019.09.013

KEYWORDS: cytochrome P450 gene; MDR1 gene polymorphisms; P-gp expression; tacrolimus; therapeutic drug concentration

© 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
xenobiotics from inside to outside the cell in order to prevent cytotoxicity, and limits luminal absorptions as well. On the other hand, systemic clearance of TAC is performed mainly via CYP3A5 isoenzymes and, to a lesser extent, via CYP3A4, which belong to cytochromes P450 superfamily expressed in the gut and liver. There is a possibility that polymorphism of these genes can cause significant phenotypic differences in their expression. Polymorphism of the MDR1 gene will affect drug absorption, and that of CYP3A5 will affect systemic clearance. This may correlate with interindividual variation in the pharmacokinetics of TAC and hence affect the therapeutic drug level. Racial differences in polymorphisms of this gene have been reported. Despite the use of TAC in clinical practice for a long time, its optimal use and role in pharmacogenetics in the individualization of the therapy is still in infancy, and singling out a starting dose to achieve a therapeutic level is cumbersome in day-to-day clinical practice. Moreover, all polymorphisms may not be clinically relevant to all populations. There is a paucity of data from northern Indian patients, particularly studies combining the MDR1 gene and CYP3A5 in the same cohort of patients and their effect on trough levels of TAC in the early posttransplantation period. This study was conducted to evaluate the influence of MDR1 and CYP3A5 gene polymorphisms on daily TAC dosage in northern Indian renal transplant patients so that pharmacogenetics could be used to individualize the therapy.

METHODS

Patients

In this prospective observational study, a total of 255 living donor renal transplant patients were recruited at our institute between October 2015 and September 2018. We recruited only those kidney transplant patients who met the following inclusion criteria: (i) TAC-based immunosuppressive regimens; (ii) no delayed graft function; and (iii) no clinical history of taking medications known to interact with calcineurin inhibitors, such as antimycotics (fluconazole and ketoconazole), calcium channel blockers (diltiazem, nicardipine, and verapamil), macrolide antibiotics (erythromycin and clarithromycin, and antiepileptics (phenytoin and carbamazepine). The initial dose of tacrolimus (Tacromus, Zydus, India) was 0.15 mg/kg per day in 2 divided doses from day minus 2 of transplantation, and the dose was then adjusted to achieve trough blood TAC concentration (Co) of 8 to 12 ng/ml at 12 hours, which is advocated for first 3 months of transplantation at our institute.

Tacrolimus Trough Level Monitoring and C/D Ratio Assessment

Blood trough TAC concentration (Co) was measured by chemiluminescent microparticle enzyme immunoassay (Abbott Co., Ltd., Plano, TX) with 200 µl blood in ethylenediamine tetraacetic acid (EDTA) tubes after 12 hours at the previous dose. The daily TAC dose was recorded, and weight-adjusted doses (daily TAC requirement) were calculated by the ratio of daily TAC dose/weight (mg/kg per day). TAC trough blood concentration was measured and then dose normalized with a corresponding dose using a TAC Co/weight-adjusted dose ratio (ng/ml per mg/kg per day).

Genotype Analysis

DNA Isolation and Genotyping

All recipients were also genotyped for the SNP of CYP3A5 at intron 3 A6986G (the *3 or *1 allele, rs776746), MDR1 at exons 12 (C1236T,rs128503), 21 (G2677A/T,rs2032582), and 26 (C3435T,rs1045642). In brief, peripheral blood samples (1.0 ml) were collected in EDTA-treated tubes and genomic DNA was extracted with a QIA amp Blood kit (Qiagen, Hilden, Germany) and stored at −20 °C. The SNPs were identified using the polymerase chain reaction–restriction fragment length polymorphism method. The primers, restriction enzymes, and polymerase chain reaction conditions are shown in Table 1 as used in the previous study.

P-gp Expression Assay

The P-gp expression on lymphocytes was analyzed from whole blood. A 50-µl quantity of heparinized blood was incubated with 20 µl phycoerythrin-conjugated human anti–P-gp mAb (BD Pharmingen, San Diego, CA) and 20 µl phycoerythrin-conjugated matched-isotype control antibody for 30 minutes at room temperature. Then, red blood cells were lysed with BD FACS lysing solution and washed twice in phosphate-buffered saline solution. Subsequently, peripheral blood mononuclear cells were fixed with 0.4% paraformaldehyde and analyzed on a FACS Canto (Becton Dickinson, San Diego, CA). At least 10,000 cells were counted and analyzed and separated according to
their forward and side scatter characteristics. Results are expressed as the percentage of positive cells for P-gp and relative fluorescence intensity as performed in our previous study.12

Statistical Analyses
Data were analyzed using IBM SPSS software version 20 (IBM Corp., Armonk, NY). The categorical values were presented as frequencies and percentages, and the continuous variables as mean values with standard deviations. The Student t test was used to compare the mean values between the 2 groups when appropriate. One-way analysis of variance using Bonferroni (Dun) methods for multiple comparisons was used to find significant differences in mean values between the groups.

RESULTS
Demographic characteristics of the patients are summarized in Table 2. A total of 248 living donor kidney transplant recipients (207 male and 41 female, mean age 34.40 ± 10.77 years), were enrolled. The native kidney diseases of the recipients included 110 cases of chronic glomerulonephritis, 65 of interstitial nephropathy, 21 of diabetic nephropathy, 8 of chronic kidney disease of unknown etiology, 7 of autosomal-dominant polycystic kidney disease, 7 of diffuse global glomerulosclerosis, 3 of Alport syndrome, and 27 cases of other, undefined causes.

Table 2. Demographic and clinical characteristics of the renal transplant recipients
| Characteristics                  | Values |
|----------------------------------|--------|
| Sex                              |        |
| Male                             | 207 (83.5%) |
| Female                           | 41 (16.5%)  |
| Mean age (yr)                    | 34.40 ± 10.77 (18–60) |
| Height (cm)                      | 162.05 ± 11.27 |
| Weight (kg)                      | 55 ± 9.63  |
| Body mass index (kg/m²)          | 20.85 ± 2.46  |
| Serum creatinine at discharge (mg/dl) | 1.117 ± 0.287 (0.49–2.29) |
| Native kidney disease            |        |
| CGN                              | 110 (44%) |
| CIN                              | 65 (26%)  |
| Diabetic kidney disease          | 21 (9%)   |
| CKDu                             | 8 (3%)    |
| ADPKD                            | 7 (3%)    |
| DGGS                             | 7 (3%)    |
| Alport syndrome                  | 3 (1%)    |
| Others                           | 27 (11%)  |
| Tacrolimus dose and adjusted level |        |
| TAC dose (mg/day)                | 6.19 ± 1.91 |
| Weight-adjusted dose (mg/kg per day) | 0.118 ± 0.038 |
| TAC level (Co) (ng/ml)           | 11.91 ± 4.47  |
| Dose-adjusted TAC (ng/ml per mg/kg per day) | 119.53 ± 79.80 |

Table 1. Primers, restriction enzymes, and polymerase chain reaction conditions used for identifying single nucleotide polymorphisms

| Marker | Primer sequence | Primer annealing conditions | Enzyme | Allele | Restriction digestion product size |
|--------|-----------------|-----------------------------|--------|--------|-----------------------------------|
| CYP3A5*1/*3 | F 5’-CATCGATTAGTGGACAAAGTAGACA-3’ | 55 °C for 1 min | SspI | *1 | 148, 125, 20 (W)  |
|         | R 5’-GCTGCAAACGAGGGAAAGAAT-3’      |                          |       | *3 | 168, 125 (M)  |
| MDR C3435T | F 5’-TCTTTCGAGCTCCTGATG-3’            | 81 °C for 30 s | SauII | C  | 39, 158 (W)  |
|         | R 5’-AAGGGCGTATCGTTGCGTC-3’          |                          |       | T  | 197 (M)  |
| MDR C1238T | F 5’-TACTGCTGCTCCTG4ATTGCG-3’        | 63.7 °C for 30 s | Haelli | C  | 269, 97 (W)  |
|         | R 5’-CTGACTCAGCAGCACACAAATG-3’       |                          |       | T  | 269, 62, 35 (M)  |
| MDR G2677T | F 5’-TGAACCTAGTATGGTCAGC-3’          | 64.3 °C for 30 s | Banl | G  | 224 (W)  |
|         | R 5’-TTAGTTTGACTCACTCGC-3’          |                          |       | T  | 198, 26 (M)  |

ADPKD, autosomal dominant polycystic kidney disease; CGN, chronic glomerulonephritis; CIN, chronic interstitial nephritis; CKDu, chronic kidney disease of unknown etiology; DGGS, diffuse glomerulosclerosis; TAC, tacrolimus.
Table 3. Genotype and allele distribution of CYP3A5 and MDR1 gene in renal transplant recipients

| CYP3A5 A6986G genotype | Genotypes   | Number (%)          |
|-------------------------|-------------|---------------------|
| AA                      | *1/*1 (%)   | 31 (12.5%)          |
| AG                      | *1/*3 (%)   | 76 (31.0%)          |
| GG                      | *3/*3 (%)   | 82 (33.6%)          |
|                         | A allele    | 301 (60.68%)        |
|                         | G allele    | 340 (68.55%)        |

| MDR1 genotype | CC (%) | CT (%) | TT (%) | C allele | T allele | A allele | G allele |
|---------------|--------|--------|--------|----------|----------|----------|----------|
| C1236T        | 109 (43.95%) | 111 (44.75%) | 28 (11.29%) | 329 (66.33%) | 167 (33.66%) | 25 (5.04%) | 302 (60.88%) |
| G2677T/A      | 99 (39.91%)  | 89 (35.88%)  | 15 (6.04%)  | 302 (60.88%) | 169 (34.07%) | 25 (5.04%) | 302 (60.88%) |
| C3435T        | 29 (11.69%)  | 137 (55.24%) | 82 (33.06%) | 195 (39.31%) | 301 (60.68%) |          |          |

observed in 156 (31.45%) and 340 (68.55%) recipients, respectively.

For MDR1 C1236T, the genotypes CC, CT, and TT were observed in 109 cases (43.95%), 111 cases (44.75%), and 28 cases (11.29%), respectively; and C and T alleles were found in 329 cases (66.33%) and 167 cases (33.66%), respectively. The MDR1 G2677T/A genotypes wild-type GG, heterozygous mutant GT and GA, homozygous mutant TT and AA, and alleles G, T, and A frequencies were 99 recipients (39.91%), 89 (35.88%), 15 (6.04%), 302 (60.88%), 169 (34.07%), and 25 recipients (5.04%), respectively. Moreover, in MDR1 C3435T mutation, the frequencies of CC, CT, and TT genotypes and C and T alleles were 29 (11.69%), 137 (55.24%), 82 (33.06%), 195 (39.31%), and 301 (60.68%), respectively, in our cohort (Table 3).

Effect of CYP3A5 A6986G Genotype on TAC Level and Their Disposition

According to CYP3A5 genotypic variations, recipients were mainly of 2 types: expressor (*1/*1 homozygous and *1/*3 heterozygous), and nonexpressor (*3/*3 homozygous). The TAC dose requirement to achieve target level was significantly higher in CYP3A5*1/*1 (0.138 ± 0.023 mg/kg per day) than that of CYP3A5*3/*3 (0.11 ± 0.04 mg/kg per day; P = 0.015) and comparable to CYP3A5*1/*3 (0.122 ± 0.036 mg/kg per day; P = 0.381). Daily TAC dose was significantly lower in CYP3A5*3/*3 (5.63 ± 1.65 mg/d) than in CYP3A5*1/*1 (7.01 ± 1.64 mg/d; P = 0.014) and CYP3A5*1/*3 (6.68 ± 2.09 mg/d; P = 0.003) (Figure 1a and b).

The TAC level was significantly lower in CYP3A5*1/*1 (7.39 ± 3.36 ng/ml) than that of both the genotypes CYP3A5*1/*3 (11.42 ± 4.05 ng/ml; P = 0.001) and CYP3A5*3/*3 (13.33 ± 4.26 ng/ml; P < 0.001). Moreover, the TAC level was also significantly lower in CYP3A5*1/*3 than in CYP3A5*3/*3 (P = 0.022). CYP3A5*1/*1 patients had a lower level of dose-adjusted TAC (54.73 ± 27.33 ng/ml per mg/kg per day) to achieve target blood concentration than that of CYP3A5*1/*3 (109.73 ± 70.84 ng/ml per mg/kg per day; P = 0.022) and CYP3A5*3/*3 patients (141.90 ± 85.02 ng/ml per mg/kg per day; P < .001), and the dose-adjusted TAC level was also significantly lower in CYP3A5*1/*3 than in CYP3A5*3/*3 (P = 0.043) patients (Figure 1c and d)

Effect of MDR1 Genotype in Recipient on TAC Dosing and Their Disposition

Considering the possible influence of MDR1 SNPs on TAC pharmacokinetics in recipients, we finally assessed the effects of SNPs of MDR1 on TAC dosing. As shown in Figures 2 and 3, we did not find any significant difference in TAC dose requirement, TAC C0, and dose-adjusted TAC level among the recipients with MDR1 at position C1236T CC, CT, and TT genotype (Figure 2a–d) and among those with C3435T CC, CT, and TT genotype (Figure 3a–d).

However, patients with G2677T/A homozygous mutant TT+AA (0.14 ± 0.034 mg/kg per day) had significantly higher daily TAC dose per weight than wild-type GG (0.10 ± 0.033 mg/kg per day; P < 0.001) and heterozygous mutant GT+GA (0.11 ± 0.039 mg/kg per day; P = 0.327) genotype to achieve target trough levels (Figure 4a–d).

Significant differences in TAC blood trough levels and dose-normalized trough levels were observed between the groups. Homozygous mutant TT+AA (8.21 ± 2.10 ng/ml; 64.19 ± 35.09 ng/ml per mg/kg per day) displayed significantly lower TAC blood trough levels and dose-normalized trough levels than wild-type GG (12.48 ± 4.51 ng/ml, P < 0.001; 134.94 ± 73.41 ng/ml per mg/kg per day, P < 0.001) and heterozygous mutant GT+GA (12.97 ± 4.41 ng/ml, P < 0.001; 128.58 ± 89.73 ng/ml per mg/kg per day, P = 0.001) genotype (Figure 4). There were no significant differences in daily TAC dose requirements, TAC trough levels, and dose-normalized trough levels between wild-type GG and heterozygous mutant GT+GA variants.
There was no significant difference in expression of P-gp among SNPs CC, CT, and TT of the recipients with **MDR1** gene C1236T and CC, CT, and TT genotypes of **MDR** gene C3435T. However, P-gp expression was significantly higher in recipients with homozygous mutant (TT+AA; 14.47 ± 3.24) compared to the

**Figure 1.** Daily (a) tacrolimus (TAC) dose, (b) TAC dose requirement, (c) TAC concentration (Co), and (d) dose-adjusted TAC level compared between recipients with CYP3A5 expressor (*1*1) and those with nonexpressor (*1*3 and *3*3).

**Figure 2.** Daily (a) tacrolimus (TAC) dose, (b) TAC dose requirement, (c) TAC concentration (Co), and (d) dose-adjusted TAC level compared among recipients with wild-type homozygous CC, heterozygous CT, and mutant homozygous TT genotype of **MDR1** C1236T gene.
wild-type (GG; $6.08 \pm 3.42$, $P < 0.001$) and heterozygous mutant (GT+GA; $6.47 \pm 3.58$, $P < 0.001$) of MDR gene G2677T/A. However, there was no significant difference between wild-type and heterozygous mutants (Figure 5).

On analyzing the correlation of the P-gp expression, with TAC concentration and dosing, we found a significant positive correlation with daily TAC dose ($r = 0.519$, $P < 0.001$) and daily dose requirement ($r = 0.534$, $P < 0.001$) (Figure 6a and b) and

---

**Figure 3.** Daily (a) tacrolimus (TAC) dose, (b) TAC dose requirement, (c) TAC concentration (Co), and (d) dose-adjusted TAC level compared among recipients with wild-type homozygous CC, heterozygous CT, and mutant homozygous TT genotype of MDR1 C3435T gene.

**Figure 4.** Daily (a) tacrolimus (TAC) dose, (b) TAC dose requirement, (c) TAC concentration (Co), and (d) dose-adjusted TAC level compared among recipients with wild-type homozygous GG, heterozygous GT+GA, and mutant homozygous TT+AA genotype of MDR1 G2677T/A gene.
negative correlation between P-gp and TAC blood trough levels \( r = -0.702, P < 0.001 \) and dose-adjusted TAC level \( r = -0.735, P < 0.001 \) (Figure 6c and d).

**Synergistic Effect of CYP3A5 and MDR1 Genotype**

On analyzing the combined effect of CYP3A5 and MDR1 G2677T/A genotype (Table 4), we observed that patients with a combination of expressor CYP3A5*1*1 and homozygous mutant TT+AA of G2677T/A required the highest daily TAC dose to meet the target trough level of TAC. Moreover, the lowest daily TAC dose requirement was found while melding patients with nonexpressor CYP3A5*3*3 and wild-type GG of G2677T/A genotype.

On multiple comparison test using analysis of variance and the Bonferroni method to see the combined effect of CYP3A5 *1*1, *1*3, and *3*3 genotypes and MDR1 G2677T/A genotypes, there were significant differences in dose requirement with MDR G2677T GG \( (P = 0.003) \) and TT/AA \( (P = 0.024) \) genotypes. With MDR G2677T GG, the daily TAC dose requirement to achieve target level was significantly higher in GG*1*1 \( (0.135 \pm 0.012 \text{ mg/kg per day}) \) than that of GG*1*3 \( (0.106 \pm 0.032 \text{ mg/kg per day}; P = 0.017) \) and GG*3*3 \( (0.101 \pm 0.027 \text{ mg/kg per day}; P = 0.002) \) genotype. In MDR G2677T TT/AA variant, the daily TAC dose requirement to achieve target concentration was significantly lower in TT/AA*3*3 \( (0.116 \pm 0.021 \text{ mg/kg per day}) \) than that of both TT/ AA*1*1 \( (0.147 \pm 0.032 \text{ mg/kg per day}; P = 0.035) \) and

---

**Figure 5.** P-glycoprotein (P-gp) expression in different variants at positions C1236T, C3435T, and G2677T/A of MDR1 gene.

**Figure 6.** Correlation of P-glycoprotein (P-gp) expression with tacrolimus (TAC) dose, daily TAC dose requirement, TAC level, and dose-adjusted TAC level. There was (a,b) a positive correlation with TAC dose and daily TAC dose requirement and (c,d) a negative correlation with TAC level and dose-adjusted TAC level.
Table 4. Daily tacrolimus (TAC) dose requirement in different combinations of MDR G2677T/A and CYP3A5 genotype to achieve target TAC trough concentration

| Genotype combinations | Recipients (n) | Dose requirement (mg/kg per d) |
|-----------------------|---------------|-------------------------------|
| GG*3*3                | 56            | 0.101                         |
| GG*1*1                | 10            | 0.135                         |
| GG*1*3                | 35            | 0.106                         |
| GAV/GT*1*1            | 8             | 0.128                         |
| GAV/GT*3*3            | 57            | 0.114                         |
| TT/AA*3*3             | 10            | 0.116                         |
| GA/GT*1*3             | 37            | 0.125                         |
| TT/AA*1*3             | 22            | 0.143                         |
| TT/AA*1*1             | 13            | 0.147                         |

TT/AA*1*3 (0.143 ± 0.027 mg/kg per day; P = 0.049) genotype (Table 5).

**DISCUSSION**

In this study, we observed that the expressor (CYP3A5*1*1) of CYP3A5 required a higher TAC dose than the nonexpressor to achieve the target trough concentration, and the mean dose difference between the 2 was significant. We also found the melding effect of the combination of expressor and homozygous mutant SNPs of MDR1 gene G2677T/A required the highest dose per kilogram of weight, whereas the combination of nonexpressor and wild-type GG of G2677T/A genotype required the lowest dose per kilogram to meet the required trough concentration of TAC.

Variability in the pharmacokinetics of TAC depends on polymorphisms of the genes involved in transport and metabolism of the drug.13,14 P-gp, a product of the MDR1 gene, is a membrane transporter glycoprotein that acts as an efflux pump, which effluxes drugs out of cells from inside, preventing the absorption of drugs, resulting in limited availability of the drug at the site of action within the cells. P-gp is expressed on luminal cells of the intestine and affects the absorption of the drug and thus the drug level indirectly.1,5,14 In the present study, we estimated P-gp on peripheral blood lymphocytes rather than luminal tissue because it is a relatively easy and noninvasive way to assay, and the translatability into day-to-day clinical practice is relatively more than a luminal biopsy and assessing P-gp on immunohistochemistry. Systemic clearance of TAC happens via CYP3A5 isoenzymes, a member of the cytochrome P450 superfamily.1,13 The activity of these 2 proteins, which is dependent on genetic polymorphism of corresponding genes, determines the ultimate drug level.13-15

In our study, we examined gene polymorphism of membrane transporter (MDR1 C1236T, MDR1 C3435T, and MDR1 G2677T/A) and metabolizer (CYP3A5 A6986G) proteins. Among them, SNPs of MDR1 G2677T/A and CYP3A5 A6986G genes were significantly associated with drug level. Gene polymorphism of rest (MDR1 C1236T, and MDR1 C3435T) did not affect drug level. A nonsignificant association of MDR1 C1236T and MDR1 C3435T gene polymorphisms and ponderously significant association of MDR1 G2677T/A in steroid-resistant nephrotic syndrome in a large cohort of northern Indian individuals from the general population and nephrotic syndrome patients was observed in our previous study.11 In the present study, the dose-adjusted TAC level was significantly lower in TT+AA, followed by heterozygous mutant GT+GA and wild-type GG, and there were no significant differences in dose-adjusted TAC and TAC dose requirement among MDR1 C3435T and C1236T SNPs. The study further affirms the applicability of MDR1 G2677T/A gene in the assessment of drug dosing and resistance in the population of northern India. Analysis of MDR1 G2677T/A gene polymorphism, wild-type GG, heterozygous mutant GT and GA, and homozygous mutant TT and AA, were prevalent in 39.91%, 41.92%, and 18.13% in this study cohort.

The association data of TAC metabolism with MDR1 gene is not consistent and varied with the patient population. Shi et al.,16 Jun et al.,17 and Kurzawaski et al.18 have not shown an association of TAC with ABCB1 gene polymorphisms. However, several studies reported that MDR1 gene SNPs are associated with daily TAC requirement.19-24 Anglicheau et al.14 found that TAC dose requirement was generally lower in patients with exon 21 and 26 SNPs.14 The most important relationship was reported for the exon 21 and 26 SNPs.14 Hoffmeyer et al. reported that SNP in exon 26 3435C>T was associated with variations in intestinal expression and function of P-gp.23 Li et al. also showed interactive

Table 5. Multiple comparison testing with analysis of variance and Bonferroni method for daily dose requirement between different groups

| Daily tacrolimus dose requirement (mg/kg per d) in different genotype combinations |
|---------------------------------------------|
| Genotype | *1*1 | *1*3 | *3*3 | P value | Multiple comparisons |
|----------|------|------|------|---------|---------------------|
| GG       | 0.135 ± 0.012 (n = 10) | 0.106 ± 0.032 (n = 35) | 0.101 ± 0.003 (n = 58) | 0.049 | GG*1*1 vs. GG*1*3; P = 0.017 |
| GA/GT    | 0.128 ± 0.007 (n = 8) | 0.125 ± 0.037 (n = 37) | 0.114 ± 0.04 (n = 57) | — | — |
| TT/AA    | 0.137 ± 0.032 (n = 13) | 0.143 ± 0.027 (n = 22) | 0.116 ± 0.024 (n = 10) | 0.035 | TT/AA*1*1 vs. TT/AA*3*3; P = 0.049 |
| TT/AA*1*1 | 0.143 ± 0.027 (n = 22) | 0.116 ± 0.024 (n = 10) | 0.106 ± 0.04 (n = 57) | — | TT/AA*1*1 vs. TT/AA*3*3; P = 0.049 |

Kidney International Reports (2020) 5, 28-38
effects of CYP3A4, CYP3A5, and MDRI polymorphisms on TAC trough concentrations. It is possible that P-gp acts in synergy with the CYP3A subfamily in limiting intestinal absorption of various drugs. One study showed that genetic polymorphisms in exon26 (3435C>T) were correlated with the cellular expression level of P-gp in relation to ABCB1 mRNA stability and/or the protein’s timing of cotranslational folding.37

In a recent study from southern India, Fernando et al. also did not show an association of TAC with the ABCB1 gene; however, they studied only C3435T. Other genes G2677T/A, C1236T, and P-gp expression have not been studied. We studied all 3 genes including P-gp expression and found an association with G 2677T/A, which is consistent with our previous other study findings as well. In order to analyze the functional part of MDRI SNPs, we observed that P-gp expression was significantly higher in recipients with homozygous mutant (TT+AA) compared to the wild-type (GG) and heterozygous mutant (GT+GA) at position G2677T/A. There was a significant negative correlation between P-gp expression and dose-adjusted TAC level.

The CYP3A5 enzyme is responsible mainly for hepatic elimination of TAC. It may potentially affect TAC pharmacokinetics, particularly in patients with CYP3A5/4 gene mutations. The CYP3A5 gene polymorphism accounts for a key element of the interindividual variability observed with TAC bioavailability.

Analysis of the CYP3A5 A6986G gene polymorphism shows the almost equal prevalence of expressor (CYP3A5*1*1/*1*3, 50.41%) and nonexpressor (CYP3A5*3*3, 49.59%) in our study population. Among expressors, the prevalence of CYP3A5*1*3 polymorphism (37.9%) is higher than that of CYP3A5*1*1 (12.5%). CYP3A5 SNPs are distributed differently among races. The CYP3A5*1 allele was found in 5% to 15% of Caucasians, 15% to 35% of Asians, 25% of Mexicans, and 45% to 73% of African Americans, which is similar to our study. In another study from northern India, Singh et al. showed the distribution of CYP3A5 SNPs as expressor in 54.54% and nonexpressor 45.45%. Loh et al., in a study of Asian renal transplant populations, also showed expressor in 51% and nonexpressor in 49%. These prevalence findings of expressor and nonexpressor are similar to our findings of expressor in 50.41% and nonexpressor in 49.59%. However, a small Indian transplant population study of 100 patients by Ashivaaid et al. reported that the distribution of CYP3A5*1*1, CYP3A5*1*3, and CYP3A5*3*3 SNPs among were 3%, 62%, and 35%, respectively. The prevalence of homozygous expressor CYP3A5*1*1 (3%) was less than 12% in our study.

We have clearly observed that among CYP3A5 genotypic variants, dose-adjusted TAC level was significantly lower, and the TAC dose required to achieve the target level was significantly higher, in CYP3A5*1*1 than those of CYP3A5*1*3 and CYP3A5*3*3. A similar observation was made in other studies.

In this study, we tried to observe the melding effect of CYP3A5 and MDRI genotype together. The study evidently showed that the daily TAC dose requirement was highest with CYP3A5*1*1 and homozygous mutant TT+AA of G2677T/A genotype, and lowest with CYP3A5*3*3 and wild-type GG of G2677T/A genotype. To achieve the therapeutic TAC level of 8 to 12 ng/ml, we need to start the TAC dose at 0.147 mg/kg body weight in cases with a combination of mutant of G2677T/A and expressor (TT/AA*1*1), and at 0.101 mg/kg BW in cases of combination of wild-type G2677T/A and nonexpressor (GG*3*3) genotype.

The study adds to the value on the existing literature in the sense that we used both MDRI gene and CYP p450 SNPs, both having an independent effect on TAC level, in the same cohort of patients. The study has potential utility in terms of providing a numerical figure to determine the dose of tacrolimus in terms of milligrams per kilogram per day to achieve initial target level in early posttransplantation, depending on the SNP combination.

**CONCLUSION**

To conclude, the CYP gene and MDRI gene polymorphisms affect the TAC dose required to achieve the target trough concentration. Expressors of CYP require a higher dose than nonexpressors. The homozygous mutant SNP of G2677T/A requires a higher dose than the heterozygous and wild-type genotypes. The combinations of expression (CYP) and mutant (MDRI) required the highest dose, and the nonexpressor and wild-type (GG of G2677T/A) genotype the lowest dose, to achieve the target trough level.

**DISCLOSURE**

All the authors declared no competing interests.

**ACKNOWLEDGMENTS**

This study has been completed with a senior research fellowship grant from the Indian Council of Medical Research, New Delhi, India.
REFERENCES

1. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 1997;54:925–975.

2. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant. 1997;12:1668–1671.

3. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077–6080.

4. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735–7738.

5. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron. 1997;77:284–289.

6. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457–473.

7. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation. 2008;85 (7 Suppl):S19–S24.

8. Bates SE, Wilson WH, Fojo AT, et al. Clinical reversal of multidrug resistance. Stem Cells Dayt Ohio. 1996;14:56–63.

9. Li D, Zhang G-L, Lou Y-Q, et al. Genetic polymorphisms in CYP3A4, CYP3A5 and ABCB1 haplotype in mainland Chinese Han, Uygun and Kazakh ethnic groups. J Clin Pharmac Ther. 2007;32:89–95.

10. Chowbay B, Zhou S, Lee EJD. An interethnic comparison of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant. 1997;12:1668–1671.

11. Provenzani A, Santeusanio A, Mathis E, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013;19:9156–9173.

12. Prasad N, Jaiswal AK, Agarwal V, et al. Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in childhood nephrotic syndrome: a longitudinal study. Cytokine. 2015;72:190–196.

13. Provenzani A, Santeusanio A, Mathis E, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013;19:9156–9173.

14. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14:1889–1896.

15. Loh PT, Lou HX, Zhao Y, et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc. 2008;40:1690–1695.

16. Shi Y, Li Y, Tang J, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013;512:226–231.

17. Jun KR, Lee W, Jang MS, et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation. 2009;87:1225–1231.

18. Kurzawski M, Dąbrowska J, Dzielawonski K, et al. CYP3A and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014;15:179–188.

19. Akbas SH, Bilgen T, Keser I, et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc. 2006;38:1290–1292.

20. Provenzani A, Notarbortolo M, Labbozzetta M, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med. 2011;28:1093–1102.

21. Herrero MJ, Sánchez-Plumed J, Galiana M, et al. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. Transplant Proc. 2010;42:3134–3136.

22. Elens L, Capron A, Kerckhove VV, et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics. 2007;17:873–883.

23. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473–3478.

24. Tsujiha N, Sato S, Tada H, Li Z, Ohyama C, Sato K, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004;78:1182–1187.

25. Li JL, Liu S, Fu Q, et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tacrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015;16:1355–1365.

26. Song P, Lamba JK, Zhang L, et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol. 2006;46:373–379.

27. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A4 and P-glycoprotein. Clin Pharmacokinet. 2001;40:159–168.

28. Fernando ME, Sellappan M, Srinivasa Prasad ND, et al. Influence of CYP3A5 and ABCB1 polymorphism on tacrolimus drug dosing in South Indian renal allograft recipients. Indian J Nephrol. 2019;29:261–266.

29. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211–2221.

30. Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011;91:300–308.
31. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev*. 2002;54:1271–1294.

32. Singh R, Srivastava A, Kapoor R, et al. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. *Naunyn Schmiedebergs Arch Pharmacol*. 2009;380:169–177.

33. Ashavaid T, Raje H, Shalia K, Shah B. Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients. *Indian J Nephrol*. 2010;20:146–151.

34. López-Montenegro Soria MA, Kanter Berga J, Beltrán Catalán S, et al. Genetic polymorphisms and individualized tacrolimus dosing. *Transplant Proc*. 2010;42:3031–3033.